Indivior (INDV)

 

INDV Share PerformanceMore

52 week high421.50 23/08/17
52 week low246.50 01/09/17
52 week change 111.70 (39.71%)
4 week volume45,495,017 19/11/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Indivior NDA for schizophrenia drug accepted by FDA

The US Food and Drug Administration has accepted the Indivior's new drug application (NDA) for RBP-7000, an investiga...

Indivior's RBP-7000 NDA Accepted by FDA

RNS Number: 0587Z Indivior PLC 12 December 2017 Indivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot A Novel Sustained-Release Candidate for Treatment of Schizophrenia Slough, UK and Richmond, VA, 12 December 2017 - Indivior PLC (LON: INDV) (the 'Company') today announces that the U.S. Food and Drug Administration (FD...

Indivior to issue shares under LTIP

Indivior has issued 5,000,000 ordinary shares to satisfy the vesting of share awards under its long-term incentive plan. At 8:...

Additional Listing

RNS Number: 7239Y Indivior PLC 08 December 2017 Indivior PLC (the "Company") - Block listing of shares Application has been made to the UK Listing Authority and the London Stock Exchange for a block listing of 5,000,000 Ordinary Shares of US$ 0.10 each to trade on the London Stock Exchange and to be admitted to the Official List. The shares will be issued...

OPEC oil production cut fails to lift FTSE

The price of Brent crude oil surged 2.3% to $64.10 per barrel after the oil cartel OPEC chose to extend production cuts until...

FTSE falls amid Corbyn 'threat' to banks

On Thursday evening, a speech by Labour leader Jeremy Corbyn rattled investors after he said he was a 'threat' to big ban...

Indivior's Sublocade gets FDA approval

The US Food and Drug Administration has approved Indivior's Sublocade for the treatment of opioid addiction. Indivior s...

FDA Approves SUBLOCADE (TM)

RNS Number: 1031Y Indivior PLC 01 December 2017 Attach pdf http://www.rns-pdf.londonstockexchange.com/rns/1031Y_-2017-12-1.pdf FDA Approves SUBLOCADE TM (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use Disorder SUBLOCADE Expected to be Available...

Latest discussion posts More

  • Re: Topped up

    It's make! For a stellar share today this gets very little chat coverage.
    1-Dec-2017
    MyHobby
  • Re: Topped up

    The opioid decision by the FDA is today eh? Any more feelings either way. It could be a make or break.
    30-Nov-2017
    MyHobby
  • Re: Topped up

    Very glad I topped up at #2.95, don't often get a 35% increase in 2 months. Thinking of top slicing, but on the whole, I think the fact that the DoJ case is well provided for, ...
    1-Nov-2017
    picstloup

Users' HoldingsMore

Users who hold Indivior also hold..

Codes & Symbols

ISINGB00BRS65X63
SymbolsINDV, LSE:INDV, INDV.L, INDV:LN, LON:INDV, XLON:INDV

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account